LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube,
wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the
forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a
potentially groundbreaking multi-cancer detection model contributing to its
mission to transform early cancer diagnostics. Leveraging ultra-low pass whole
genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a
promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at
an early stage when treatment is the most effective. However, Flamingo has the
potential to overcome these limitations by harnessing the power of AI to analyze
minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states
Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our
commitment to change cancer diagnostics in a transformative way, ultimately
offering clinicians a powerful tool to detect cancer across diverse omic
layers."
The Company believes that no single model or molecular modality will reach the
requisite sensitivity and specificity throughout the entire patient journey for
personalized, precision medicine, from early detection, to predicting the
effectiveness of various treatment options, to monitoring the response to
therapy within days of starting it, to detecting recurrence at the earliest
possible moment. Therefore, our AI/machine learning platform, The Cube,
integrates multi-omic data, offering a uniquely comprehensive approach to cancer
detection by leveraging a library of trained models for multiple omic layers.
One such model Flamingo focuses on is the detection of cancer from ultra-low
pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early
cancer detection with RenovaroCube's engine. By utilizing as few as only
200,000 cell-free DNA fragments per sample, integrating fragment lengths,
sequence motifs and employing a meticulously designed neural network, Flamingo
achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers,
Flamingo contributes to the development of non-invasive diagnostics to detect
cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm
shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its
introduction, we are one step closer to realizing our vision of a world where
cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international
research institutions, clinical cancer centers and all stakeholders to join in
the early research use application of our AI/machine learning platform to
advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-
diagnosing-cancers-and-infectious-diseases-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of
the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform
cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland
Venture Challenge (startup of the year) by scientists of the UMC Utrecht
(https://www.umcutrecht.nl/). Its ambition is to transform cancer care by
enabling faster and more reliable diagnoses, particularly in the context of
cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA
(https://en.wikipedia.org/wiki/Circulating_tumor_DNA)) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline and platform. All statements other than historical facts are forward-
looking statements, which can be identified by the use of forward-looking
terminology such as "believes," "plans," "expects," "aims," "intends,"
"potential," or similar expressions. Actual events or results may differ
materially from those projected in any of such statements due to various
uncertainties, including as set forth in Renovaro's most recent Annual Report on
Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and Renovaro Inc. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
Â